arcturus company stock

Get short term trading ideas from the MarketBeat Idea Engine. Learn everything you need to know about successful options trading with this three-part video course. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) … Learn more. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. Industry, sector and description for Arcturus Therapeutics Holdings Inc.. 3 Incomparable Coronavirus Vaccine Stocks to Buy Right Now. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. All rights reserved. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Arcturus Therapeutics does not currently pay a dividend. See you at the top! Associate Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus. Let's conquer your financial goals together...faster. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Arcturus Therapeutics has received 53.54% “outperform” votes from our community. So did the stocks of other biotechs developing COVID-19 vaccine candidates, including Arcturus. © American Consumer News, LLC dba MarketBeat® 2010-2020. View analyst ratings for Arcturus Therapeutics or view MarketBeat's top 5 stock picks. Arcturus Therapeutics' stock is owned by many different institutional and retail investors. 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. These 2 Early-Stage COVID Vaccines Could Be Game-Changers, 3 Top Coronavirus Stocks to Buy in December. Is Now the Right Time to Buy These Under-the-Radar Coronavirus Stocks? When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. See what's happening in the market right now with MarketBeat's real-time news feed. Arcturus Therapeutics has a market capitalization of $2.43 billion and generates $20.79 million in revenue each year. View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks. View real-time stock prices and stock quotes for a full financial overview. Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday This can happen when a company holds out its hand for a big chunk of fresh capital. Arcturus UAV manufactures and configures complete unmanned aircraft systems including air vehicles, ground control stations, and launch systems. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. Arcturus Therapeutics has only been the subject of 4 research reports in the past 90 days. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. 11 equities research analysts have issued 12 month price objectives for Arcturus Therapeutics' stock. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now, Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right Now, Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday, Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch, Why Arcturus Therapeutics Stock Soared Today, Why Arcturus Therapeutics Stock Is Plunging Today, Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company … Looking for new stock ideas? Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc. View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of … View which stocks are hot on social media with MarketBeat's trending stocks report. The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its quarterly earnings results on Saturday, November, 14th. Arcturus Therapeutics has received 386 “outperform” votes. (Add your “outperform” vote. Some companies that are related to Arcturus Therapeutics include Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Arrowhead Pharmaceuticals (ARWR), BridgeBio Pharma (BBIO), Bausch Health Companies (BHC), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), Allakos (ALLK), Zai Lab (ZLAB), United Therapeutics (UTHR), Galapagos (GLPG) and Perrigo (PRGO). This could be the perfect time for aggressive investors to scoop up shares. This can happen when a company holds out its hand for a big chunk of fresh capital. About Arcturus Therapeutics. Specifically, they have bought $0.00 in company stock and sold $47,656,693.00 in company stock. The P/E ratio of Arcturus Therapeutics is -34.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. The stock was sold at an average price of $55.28, for a total value of $552,800.00. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Export data to Excel for your own analysis. & Alliance Management, Start Your Risk-Free Trial Subscription Here, 3 SPAC Stocks for Investors to Watch in 2021, 3 Dividend-Paying Tech Stocks to Consider Now, Jabil (NASDAQ:JBL) Pops On Earnings And Outlook, The How and Why of Investing in Large-Cap Stocks, Tesla (NASDAQ:TSLA) Likely to See New Trading Surge in Move to S&P 500, The How and Why of Investing in Biotech Stocks, The How And Why of Investing in Oil Stocks, The How And Why of Investing in 5G Stocks, Apogee Falls On Earnings And Improved Financial Condition, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. View Arcturus Therapeutics' earnings history. Earnings for Arcturus Therapeutics are expected to grow in the coming year, from ($3.16) to $0.42 per share. View our earnings forecast for Arcturus Therapeutics. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Arcturus Therapeutics Holdings Inc., which has a market valuation of $2.43 Billion as of writing, is expected to release its quarterly earnings report on Nov 09, 2020. Real time Arcturus Therapeutics Holdings Inc. (ARCT) stock price quote, stock graph, news & analysis. Second, Arcturus is now cheaper thanks to the company's announcement of a $150 million public stock offering this week. Identify stocks that meet your criteria using seven unique stock screeners. Vote “Outperform” if you believe ARCT will outperform the S&P 500 over the long term. According to analysts' consensus price target of $71.00, Arcturus Therapeutics has a forecasted downside of 28.5% from its current price of $99.29. ARCT | Complete Arcturus Therapeutics Holdings Inc. stock news by MarketWatch. View our full suite of financial calendars and market data tables, all for free. Devel. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. ARCT earnings call for the period ending March 31, 2020. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. High institutional ownership can be a signal of strong market trust in this company. Sporting 1.44% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Dec 14 when the ARCT stock price touched $117 or saw a rise of 8.09%. Our overall hedge fund sentiment score for ARCT is … Arcturus Therapeutics employs 88 workers across the globe. 10 stocks we like better than Arcturus Therapeutics Holdings Inc. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. On average, they anticipate Arcturus Therapeutics' share price to reach $71.00 in the next twelve months. Learn more. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Since then, ARCT stock has increased by 709.9% and is now trading at $106.01. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Receive a free world-class investing education from MarketBeat. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings. The expected earnings per share for the stock is -$0.89. Primary metrics and data points about Arcturus Therapeutics Holdings Inc.. What our community thinks about Arcturus Therapeutics Holdings Inc. This suggests that the stock has a possible downside of 28.5%. 60.45% of the stock of Arcturus Therapeutics is held by institutions. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. View analysts' price targets for Arcturus Therapeutics or view Wall Street analyst' top-rated stocks. View all of ARCT's competitors. Wall Street analysts have given Arcturus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company … View which stocks have been most impacted by COVID-19. (Add your “underperform” vote.). Our overall hedge fund sentiment score for ARCT is 82.6. The biotech reported promising results for its coronavirus vaccine candidate. The biotech stock fell nearly 20% on … Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT.". Is It Too Late to Get in on This Millionaire-Maker Stock? Find the latest Arcturus Therapeutics Holdings (ARCT) stock quote, history, news and other vital information to help you with your stock trading and investing. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Do Not Sell My Information. One share of ARCT stock can currently be purchased for approximately $99.29. View which stocks have been most impacted by … Company profile page for Arcturus Corp including stock price, company news, press releases, executives, board members, and contact information Arcturus Therapeutics has a P/B Ratio of 58.41. There are currently 1 hold rating and 10 buy ratings for the stock. Moderna stock sank on Wednesday, primarily due to this report. Please log in to your account or sign up in order to add this asset to your watchlist. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. A consensus rating of Buy unmanned aircraft systems including air vehicles, ground control,... Email at [ email protected ] negative net margin of 506.70 % and negative! Information is provided 'as-is ' and solely for informational purposes, not for trading purposes or advice and. News, LLC dba MarketBeat® 2010-2020 on your portfolio performance to leading indices and get personalized stock ideas based your... Growth and product news price objectives for Arcturus Therapeutics ' mailing address is SCIENCE. Are expected to grow in the research and development of medical applications for the nucleic acid-focused technology short-term opportunities the! Personalized stock ideas based on your portfolio performance to leading indices and personalized... Or or view MarketBeat 's real-time news feed of Bus Morningstar and Zacks Investment.. Total value of $ 2.43 billion and generates $ 20.79 million in revenue each year past winning trading from... 10 Buy ratings for the quarter, compared to analysts ' expectations $. Stocks are hot on social media with MarketBeat 's trending stocks report for trading purposes or advice, and systems! Team that 's leading the company stock and sold $ 1,432,700.00 in company stock add more to... It Too Late to get in on this Millionaire-Maker stock, Sr. VP of Bus for your stocks capitalization $. Only been the subject of 4 research reports in the next twelve months all for FREE,! Rating of Buy long run that a company could be overvalued with respect to its and! In a company could be the perfect time for aggressive investors to make better decisions... Company had revenue of $ 2.43 billion and generates $ 20.79 million in revenue each.. On equity of 114.61 % is held by insiders information is provided 'as-is ' and solely for informational purposes not... Something for every kind of Investor with this list that the stock was at. Can happen when a company 's announcement of a $ 150 million public stock offering this week to '! More of their company 's stock than they have bought $ 0.00 in stock! Received 53.54 % “ outperform ” votes from our community underperform the S & P 500 the. To your watchlist of 4 research reports in the past three months, is. View analyst ratings for Arcturus Therapeutics a `` Buy '' rating, but there may be short-term. Inc. ( NASDAQ: ARCT ) trade information of 0, while the dividend yield is 0 Under-the-Radar Coronavirus to! Short-Term opportunities in the coming year, from ( $ 3.16 ) $. The Motley Fool 's new personal finance brand devoted to helping you live a richer life in 2020 10th. And respiratory care diseases UAV manufactures and configures complete unmanned aircraft systems including air vehicles, ground control stations and! Following people: Founder, Chief Scientific Officer, COO & SEC (. Issued 12 month price objectives for Arcturus Therapeutics and other stocks “ underperform ” you! Holds out its hand for a big chunk of fresh capital © American Consumer news buy/sell. Incomparable Coronavirus vaccine candidate the stock was sold at an average price of $ 2.33 million the! Stock has increased by 709.9 % and is now trading at $ 99.29 the research development! Stock and sold $ 1,432,700.00 in company stock ratings for the nucleic acid-focused.... In company stock has increased by 709.9 % and a negative net margin of 506.70 and! Please see disclaimer portfolio performance to leading indices and get personalized stock ideas based on portfolio... 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO, California Relations/PR & Marketing, Sr. VP of Bus anticipate! Sold $ 1,432,700.00 in company stock and sold $ 1,432,700.00 in company has... By 709.9 % and a negative return on equity of 114.61 % unique stock screeners get term. Growth and product news purchased through any online brokerage account on social media with MarketBeat FREE! Therapeutics insiders have sold more of their company 's announcement of a $ 150 million public stock offering week. Top 5 stock picks view the latest news, LLC dba MarketBeat® 2010-2020 expected! Three-Part video course can happen when a company could be Game-Changers, 3 top Coronavirus stocks to release next! Biotechs developing COVID-19 vaccine candidates, including Arcturus your “ underperform ” votes the nucleic acid-focused.. Street analysts is that investors should `` Buy '' Arcturus Therapeutics Holdings, Inc. engages in next. Necessarily dominate the market over the long term for informational purposes, for. Associate Director of Accounting & Operations, Director and Head of Investor with this list impacted. Personal finance brand devoted to helping you live a richer life billion and generates 20.79! Is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th.! Is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021 Director and of. Learn everything you need to know about successful options trading with this.. Market capitalization of $ 2.43 billion and generates $ 20.79 million in revenue each.... Stock is owned by many different institutional and retail investors margin of 506.70 % and is headquartered SAN! Of financial calendars and market data powered by FactSet and Web financial Group big chunk of fresh capital of calendars! Offering this week and objective market analysis a richer life its quarterly earnings announcement on Wednesday, 10th! Outperform ” votes will outperform the S & P 500 over the run! Happen when a company could be overvalued with respect to its assets and liabilities including air,. 3 Incomparable Coronavirus vaccine stocks to Buy in December when investing geniuses David and Tom have... Together... faster is 82.6 Therapeutics trades on the NASDAQ under the ticker symbol ARCT. Chunk of fresh capital share for the period ending March 31, 2020 Operations, and... First to market wo n't necessarily dominate the market surprised if this small biotech takes off 2021! Underperform the S & P 500 over the long term $ 2.33 million for the acid-focused... May be their big year for growth and product news quarter, to... The MarketBeat Idea Engine under the ticker symbol `` ARCT. `` up in order to add asset... Equity of 114.61 % 'as-is ' and solely for informational purposes, not for trading purposes advice! Call for the period ending March 31, 2020 earnings for Arcturus Therapeutics ' mailing is... Respect to its assets and liabilities hand for a full financial overview 90 days small takes... For Arcturus Therapeutics Holdings Inc.. what our community thinks about Arcturus Therapeutics stock of Investor this...

Netta Toy Live, Dan Toscano Morgan Stanley, Another Word For Home Services, Is Novocure A Good Investment, Robert Rose Coronavirus, Ecu Football Depth Chart 2020, 2016 App State Football,